Protective effect of Allium hookeri water extract and its main compound, Cycloalliin, on foam cell formation in THP-1-derived macrophages

  • Harin Moon Department of Food and Nutrition, Chonnam National University, Yongbong-ro, Buk-gu, Gwangju 61186, South Korea
  • Jung-Mi Yun Department of Food & Nutrition, Chonnam National University
DOI: https://doi.org/10.29219/fnr.v69.10763
Keywords: atherosclerosis, Allium hookeri, cycloalliin, foam cells, oxidized low-density lipoprotein, THP-1

Abstract

Background: Low-density lipoproteins are oxidized and modified by macrophages. This process leads to the formation of macrophage-derived cholesterol-rich foam cells, which are a hallmark of early atherosclerosis. The accumulation of these form cells plays a crucial role in atherosclerosis progression. Allium hookeri (A. hookeri), a medicinal herb commonly used in Southeast Asia, is known for its various bioactive effects, including antioxidant, antibacterial, and antidiabetic properties. However, the repressive effect of A. hookeri extract on foam cell formation in THP-1 macrophages remains unclear.

Objective: This study aims to explore the effect of A. hookeri hot water extract (AHWE) and its primary compound, cycloalliin, on foam cell formation. This investigation involves a combined treatment of oxidized low-density lipoprotein and lipopolysaccharide to stimulate the development of atherosclerosis in vitro. Additionally, the regulatory mechanisms underlying this process were elucidated.

Design: THP-1 cells were differentiated by phorbol 12-myristate 13-acetate (PMA) (1 μM) for 48 h. Subsequently, they were treated with either AHWE or cycloalliin for 48 h. THP-1 macrophages were treated with combined ox-LDL (20 μg/mL) and LPS (500 ng/mL) for 24 h. Cell viability was assessed using MTT assays, while lipid accumulation was visualized through Oil Red O staining. The levels of corresponding proteins and mRNA were quantified using western blotting and quantitative polymerase chain reactions.

Results: THP-1 cells were differentiated with PMA (1 μM) for 48 h and then treated with or without AHWE and cycloalliin for 48 h. Subsequently, THP-1 macrophages were treated with combined ox-LDL (20 μg/mL) and LPS (500 ng/mL) for 24 h before harvesting. Ox-LDL and LPS treatment for 24 h enhanced the lipid accumulation in foam cells compared to those in untreated cells using Oil red O staining. Conversely, AHWE and cycloalliin treatment inhibited lipid accumulation in foam cells. These treatments significantly upregulated cholesterol efflux-related genes, including ATP binding cassette subfamily A member 1 (ABCA1), liver-X-receptor ɑ (LXRɑ), and peroxisome proliferator-activated receptor gamma (PPARγ) expression. Additionally, AHWE and cycloalliin decreased lipid accumulation-related genes, including lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), cluster of differentiation 36 (CD36), and scavenger receptor A1 (SR-A1) expression. Furthermore, the combined treatment of ox-LDL and LPS increased the activation and expression of nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines (tumor necrosis factor-α [TNF-α] and IL-6) compared with those in untreated cells. However, AHWE and cycloalliin suppressed the expression of NF-κB, COX-2, TNF-α, and IL-6.

Conclusions: AHWE and cycloalliin potentially play a crucial role in suppressing and protecting against early-stage foam cell formation by modulating lipid accumulation and cholesterol efflux. AHWE and cycloalliin have the potential to be effective agents for preventing atherosclerosis.

Downloads

Download data is not yet available.

References


1.
Kim TH, Son YK, Hwang KH, Kim MH. Effects of Angelica keiskei Koidzumi and turmeric extract supplementation on serum lipid parameters in hypercholesterolemic diet or P-407-induced hyperlipidemic rats. J Korean Sco Food Sci Nutr 2008; 37(6): 708–13. doi: 10.3746/jkfn.2008.37.6.708

2.
Chi L, Peng L, Pan N, Hu X, Zhang Y. The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1. Int J Mol Med 2014; 34(4): 1087–93. doi: 10.3892/ijmm.2014.1868

3.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685–95. doi: 10.1056/NEJMra043430

4.
Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8(10): 802–15. doi: 10.1038/nri2415

5.
Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251(4995): 788–91. doi: 10.1126/science.1990440

6.
Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010; 411(23–24): 1875–82. doi: 10.1016/j.cca.2010.08.038

7.
Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013; 13(10): 709–21. doi: 10.1038/nri3520

8.
Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta 2013; 424: 245–52. doi: 10.1016/j.cca.2013.06.006

9.
Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB. Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine. Eur J Pharmacol 2013; 698(1–3): 299–309. doi: 10.1016/j.ejphar.2012.08.024

10.
Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209(1): 13–22. doi: 10.1083/jcb.201412052

11.
Cai Y, Li JD, Yan C. Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun 2013; 434(3): 439–43. doi: 10.1016/j.bbrc.2013.03.092

12.
Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest 2009; 119(1): 136–45. doi: 10.1172/JCI35535

13.
Sukhorukov VN, Khotina VA, Chegodaev YS, Ivanova E, Sobenin IA, Orekhov AN. Lipid metabolism in macrophages: focus on atherosclerosis. Biomedicines 2020; 8(8): 262. doi: 10.3390/biomedicines8080262

14.
Leifer CA, Gruber E, Stelzer S, Erlich E, Sinha S. Macrophage lipid accumulation is regulated by substrate stiffness. J Immunol 2016; 196(1_Suppl): 57.5. doi: 10.4049/jimmunol.196.Supp.57.5

15.
Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease. Circ Res 2019; 124(10): 1505–18. doi: 10.1161/CIRCRESAHA.119.312617

16.
Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res 2013; 112(11): 1456–65. doi: 10.1161/CIRCRESAHA.113.301086

17.
Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, et al. Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis. Circulation 2018; 138(9): 898–912. doi: 10.1161/CIRCULATIONAHA.117.032636

18.
Shea S, Stein JH, Jorgensen NW, McClelland RL, Tascau L, Shrager S, et al. Cholesterol mass efflux capacity, incident cardiovascular disease, and progression of carotid plaque: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2019; 39(1): 89–96. doi: 10.1161/ATVBAHA.118.311366

19.
Zhang Y, Igwe OJ. Exogenous oxidants activate nuclear factor kappa B through Toll-like receptor 4 stimulation to maintain inflammatory phenotype in macrophage. Biochem Pharmacol 2018; 147: 104–18. doi: 10.1016/j.bcp.2017.11.012

20.
Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc Natl Acad Sci U S A 2000; 97(22): 12097–102. doi: 10.1073/pnas.200367697

21.
Chawla A, Boisvert WA, Lee C-H, Laffitte BA, Barak Y, Joseph SB, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7(1): 161–71. doi: 10.1016/s1097-2765(01)00164-2

22.
Malekmohammad K, Sewell RD, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules 2019; 9(8): 301. doi: 10.3390/biom9080301

23.
Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78(6): 539–52. doi: 10.1016/j.bcp.2009.04.029

24.
Kim KW, Ivanov S, Williams JW. Monocyte recruitment, specification, and function in atherosclerosis. Cells 2020; 10(1): 15. doi: 10.3390/cells10010015

25.
Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther 2022; 7(1): 131. doi: 10.1038/s41392-022-00955-7

26.
Makarov SS. NF-κB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001; 3(4): 1–7. doi: 10.1186/ar300

27.
Pamukcu B, Lip GY, Shantsila E. The nuclear factor–kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 2011;1 28(2): 117–23. doi: 10.1016/j.thromres.2011.03.025

28.
Zhang JM, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin 2007; 45(2): 27. doi: 10.1097/AIA.0b013e318034194e

29.
Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008; 105(28): 9793–8. doi: 10.1073/pnas.0802917105

30.
Guyton JR, Bays HE, Grundy SM, Jacobson TA. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014; 8(3): S72–81. doi: 10.1016/j.jacl.2014.03.002

31.
Sung J, Kim SH, Song HR, Chi MH, Park JE. Lipid-lowering treatment practice patterns in Korea: comparison with the data obtained from the CEPHEUS Pan-Asian study. J Atheroscler Thromb 2014; 21(11): 1219–27. doi: 10.5551/jat.23242

32.
Ayam VS. Allium hookeri, Thw. Enum. A lesser known terrestrial perennial herb used as food and its ethnobotanical relevance in Manipur. AJFAND 2011; 11(6): 5389–12. doi: 10.18697/ajfand.47.9330

33.
Sharma G, Gohil R, Kaul V. Cytological status of Allium hookeri Thwaites (2n= 22). Genet Resour Crop Evol 2011; 58: 1041–50. doi: 10.1007/s10722-010-9641-x

34.
Lee KW, Kim YS, Park PJ, Jeong JH. Comparison of effect of water and ethanolic extract from roots and leaves of Allium hookeri. J Korean Soc Food Sci Nutr 2014; 43(12): 1808–16. doi: 10.3746/jkfn.2014.43.12.1808

35.
Park JY, Yoon KY. Comparison of the nutrient composition and quality of the root of Allium hookeri grown in Korea and Myanmar. Korean J Food Sci Technol 2014; 46(5): 544–8. doi: 10.9721/KJFST.2014.46.5.544

36.
Myint AA, Aregay MG, Kang M, Kim BS, Lee YW, Kim J. Comprehensive study on the formation mechanism of highly bioactive compounds from Allium hookeri root using subcritical water and their antioxidant and anticancer effects. J Supercrit Fluids 2020; 157: 104709. doi: 10.1016/j.supflu.2019.104709

37.
Bae GC, Bae DY. The anti-inflammatory effects of ethanol extract of Allium hookeri cultivated in South Korea. Kor J Herbol 2012; 27(6): 55–61. doi: 10.6116/kjh.2012.27.6.55

38.
Bok SH, Seo JH, Bae CS, Kang B, Cho SS, Park DH. Allium hookeri root extract regulates asthmatic changes through immunological modulation of Th1/Th2‑related factors in an ovalbumin‑induced asthma mouse model. Mol Med Rep 2019; 20(4): 3215–23. doi: 10.3892/mmr.2019.10560

39.
Li R, Wang YF, Sun Q, Hu HB. Chemical composition and antimicrobial activity of the essential oil from Allium hookeri consumed in Xishuangbanna, southwest China. Nat Prod Commun 2014; 9(6): 863–4. doi: 10.1177/1934578X1400900636

40.
Kim S, Lee S, Shin D, Yoo M. Change in organosulfur compounds in onion (Allium cepa L.) during heat treatment. Food Sci Biotechnol 2016; 25(1): 115–9. doi: 10.1007/s10068-016-0017-7

41.
Sciences NIoA. Investigation of Allium hookeri’s functional activity and its use in developing functional foods. Jeonju: Rural Development Administration; 2016. Report No.: PJ010490.

42.
Yanagita T, Han S, Wang YM, Tsuruta Y, Anno T. Cycloalliin, a cyclic sulfur imino acid, reduces serum triacylglycerol in rats. Nutrition 2003; 19(2): 140–3. doi: 10.1016/s0899-9007(02)00857-2

43.
Yoshinari O, Shiojima Y, Igarashi K. Anti-obesity effects of onion extract in Zucker diabetic fatty rats. Nutrients 2012; 4(10): 1518–26. doi: 10.3390/nu4101518

44.
Morgan MJ, Liu Zg. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 2011; 21(1): 103–15. doi: 10.1038/cr.2010.178

45.
Yu XH, Zheng XL, Tang CK. Nuclear factor-κB activation as a pathological mechanism of lipid metabolism and atherosclerosis. Adv Clin Chem 2015; 70: 1–30. doi: 10.1016/bs.acc.2015.03.004

46.
Ha KH, Kwon HS, Kim DJ. Epidemiologic characteristics of dyslipidemia in Korea. J Lipid Atheroscler 2015; 4(2): 93–9. doi: 10.12997/jla.2015.4.2.93

47.
Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019; 7(10): e1332–e45. doi: 10.1016/S2214-109X(19)30318-3

48.
Oh K, Kim Y, Kweon S, Kim S, Yun S, Park S, et al. Korea national health and nutrition examination survey, 20th anniversary: accomplishments and future directions. Epidemiol Health 2021; 43: e2021025. doi: 10.4178/epih.e2021025

49.
Lee YH, Kwak EM, Jo M. Factors affecting cardiovascular disease in Korea adults: focusing on smoking behavior including Urine cotinine and health behaviors. J Converg Cult Technol 2021; 7(3): 293–301.

50.
Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol 2019; 112: 54–71. doi: 10.1016/j.vph.2018.08.002

51.
Wang D, Yang Y, Lei Y, Tzvetkov NT, Liu X, Yeung AWK, et al. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products. Pharmacol Rev 2019; 71(4): 596–670. doi: 10.1124/pr.118.017178

52.
Fuenzalida B, Cantin C, Kallol S, Carvajal L, Pastén V, Contreras-Duarte S, et al. Cholesterol uptake and efflux are impaired in human trophoblast cells from pregnancies with maternal supraphysiological hypercholesterolemia. Sci Rep 2020; 10(1): 5264. doi: 10.1038/s41598-020-61629-4

53.
Tousoulis D, Economou EK, Oikonomou E, Papageorgiou N, Siasos G, Latsios G, et al. The role and predictive value of cytokines in atherosclerosis and coronary artery disease. Curr Med Chem 2015; 22(22): 2636–50. doi: 10.2174/0929867322666150415145814

54.
Im YS, Gwon MH, Yun JM. Protective effects of phenethyl isothiocyanate on foam cell formation by combined treatment of oxidized low-density lipoprotein and lipopolysaccharide in THP-1 macrophage. Food Sci Nutr 2021; 9(6): 3269–79. doi: 10.1002/fsn3.2293

55.
Fu W, Fu W, Ding S, Chen Z, Jiang J, Gong Z, et al. Sodium paeonolsilate inhibits ox-LDL induced macrophage foam cell formation and inflammation in atherosclerosis. Int J Clin Exp Med 2016; 9(2): 1051–61.

56.
Unver N, McAllister F. IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev 2018; 41: 10–7. doi: 10.1016/j.cytogfr.2018.04.004

57.
Zhang Y, Yang X, Bian F, Wu P, Xing S, Xu G, et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol 2014; 72: 85–94. doi: 10.1016/j.yjmcc.2014.02.012

58.
Tong W, Chen X, Song X, Chen Y, Jia R, Zou Y, et al. Resveratrol inhibits LPS‑induced inflammation through suppressing the signaling cascades of TLR4‑NF‑κB/MAPKs/IRF3. Exp Ther Med 2020; 19(3): 1824–34. doi: 10.3892/etm.2019.8396

59.
Nguyen TQ, Duy Binh T, Pham TL, Nguyen YD, Thi Xuan Trang D, Nguyen TT, et al. Anti-inflammatory effects of Lasia spinosa leaf extract in lipopolysaccharide-induced RAW 264.7 macrophages. Int J Mol Sci 2020; 21(10): 3439. doi: 10.3390/ijms2110343

60.
Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J Mol Med (Berl) 2017; 95(11): 1153–65. doi: 10.1007/s00109-017-1575-8

61.
Chyu KY, Shah PK. HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Front Pharmacol 2015; 6: 187. doi: 10.3389/fphar.2015.00187

62.
Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(8): 1513–8. doi: 10.1161/ATVBAHA.109.191197

63.
Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol 2018; 14(8): 452–63. doi: 10.1038/s41574-018-0037-x

64.
Li S, Cao H, Shen D, Jia Q, Chen C, Xing SL. Quercetin protects against ox‑LDL‑induced injury via regulation of ABCAl, LXR‑α and PCSK9 in RAW264.7 macrophages. Mol Med Rep 2018; 18(1): 799–806. doi: 10.3892/mmr.2018.9048

65.
Nyandwi JB, Ko YS, Jin H, Yun SP, Park SW, Kim HJ. Rosmarinic acid increases macrophage cholesterol efflux through regulation of ABCA1 and ABCG1 in different mechanisms. Int J Mol Sci 2021; 22(16): 8791. doi: 10.3390/ijms22168791

66.
Li J, Xiong T, Wang T, Wang M, Wang C, Yang F, et al. Baicalein targets CD36 to prevent foam cell formation by suppressing the excessive uptake of oxLDL and accelerating ABCA1-mediated cholesterol efflux in oxLDL-induced THP-1 macrophages. J Funct Foods 2022; 97: 105253. doi: 10.1016/j.jff.2022.105253

67.
Kattoor AJ, Goel A, Mehta JL. LOX-1: regulation, signaling and its role in atherosclerosis. Antioxidants 2019; 8(7): 218. doi: 10.3390/antiox8070218

68.
Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J Am Coll Cardiol 2017; 69(22): 2759–68. doi: 10.1016/j.jacc.2017.04.010

69.
Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013; 70: 2859–72. doi: 10.1007/s00018-012-1194-z

70.
Ou HC, Song TY, Yeh YC, Huang CY, Yang SF, Chiu TH, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol (1985) 2010; 108(6): 1745–56. doi: 10.1152/japplphysiol.00879.2009

71.
Qin M, Wang L, Li F, Yang M, Song L, Tian F, et al. Oxidized LDL activated eosinophil polarize macrophage phenotype from M2 to M1 through activation of CD36 scavenger receptor. Atherosclerosis 2017; 263: 82–91. doi: 10.1016/j.atherosclerosis.2017.05.011

72.
Jiang Y, Wang M, Huang K, Zhang Z, Shao N, Zhang Y, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun 2012; 425(2): 121–6. doi: 10.1016/j.bbrc.2012.07.011

73.
Guy E, Kuchibhotla S, Silverstein R, Febbraio M. Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36o /apoEo mice. Atherosclerosis 2007; 192(1): 123–30. doi: 10.1016/j.atherosclerosis.2006.07.015

74.
Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med 2014; 46(6): e99. doi: 10.1038/emm.2014.38

75.
Duan J, Xiang D, Luo H, Wang G, Ye Y, Yu C, et al. Tetramethylpyrazine suppresses lipid accumulation in macrophages via upregulation of the ATP-binding cassette transporters and downregulation of scavenger receptors. Oncol Rep 2017; 38(4): 2267–76. doi: 10.3892/or.2017.5881

76.
Lin HC, Lii CK, Chen HC, Lin AH, Yang YC, Chen HW. Andrographolide inhibits oxidized LDL-induced cholesterol accumulation and foam cell formation in macrophages. Am J Chin Med 2018; 46(01): 87–106. doi: 10.1142/S0192415X18500052

77.
Chen XL, Liang PL, Gong MJ, Xu Y, Zhang L, Qiu XH, et al. Polyphenolics from Syzygium brachythyrsum inhibits oxidized low-density lipoprotein-induced macrophage-derived doam cell formation and inflammation. Foods 2022; 11(21): 3543. doi: 10.3390/foods11213543
Published
2025-05-27
How to Cite
Moon , H., & Yun , J.-M. (2025). Protective effect of Allium hookeri water extract and its main compound, Cycloalliin, on foam cell formation in THP-1-derived macrophages. Food & Nutrition Research, 69. https://doi.org/10.29219/fnr.v69.10763
Issue
Vol 69 (2025)
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright of their work, with first publication rights granted to SNF Swedish Nutrition Foundation. Read the full Copyright- and Licensing Statement.

 

 

Crossref
Scopus
Google Scholar
Europe PMC